Loading
Cytospire Therapeutics makes antibodies that pull a particular family of immune cells, gamma delta T cells, onto cancer cells so they kill them. Its first medicine, for bowel, head and neck and lung cancers that carry the EGFR protein, was being prepared for its first human trial in 2026.
Cytospire Therapeutics is a London biotech developing multispecific antibodies that engage gamma delta T cells across their subtypes (pan-gamma delta T cell engagers) rather than the CD3 receptor used by most T cell engagers. Its lead programme, CYT X300, is intended for EGFR-positive solid tumours such as colorectal, head and neck and non-small cell lung cancers and had not entered human testing in May 2026. On 5 May 2026 the company announced an oversubscribed GBP 61 million (USD 83 million) Series A led by 4BIO Capital, with Servier Ventures, Sound Bioventures, British Business Bank, Criteria Bio Ventures, Modi Ventures, Medical Incubator Japan and Pathway Bioventures joining existing investors Abingworth and LifeArc Ventures. Natalie Mount is chief executive.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · GBP 61 million; the release states the USD 83 million equivalent. Led by 4BIO Capital | 2026 | $83M | cytospire.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares T-cell engagers (bispecific), Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer.
Shares T-cell engagers (bispecific), Non-small-cell lung cancer.
Shares T-cell engagers (bispecific), Non-small-cell lung cancer.
Shares T-cell engagers (bispecific), Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/